Nathaniel Henning

Nathaniel Henning has extensive work experience in the field of chemical biology and therapeutic research. From August 2019 to May 2022, Henning worked as a PhD Graduate Student in the Chemical Biology Program at the University of California, Berkeley. During this time, they made significant discoveries in the development of deubiquitinase-targeting chimeras (DUBTACs) and covalent inhibitors of SARS-CoV2 Mpro. Prior to this, from September 2017 to June 2019, Henning worked as a Research Technician in the Nathanael Gray Lab at the Dana-Farber Cancer Institute. In this role, they gained valuable experience in research and laboratory techniques. Henning also worked as a Student Research Assistant in the Research Group of Professor Sunhee Choi from January 2016 to May 2017. Most recently, Henning joined Vicinitas Therapeutics as a Scientist II in May 2022.

Nathaniel Henning completed their high school education at Walt Whitman High School from 2009 to 2013. Nathaniel then pursued a Bachelor of Arts degree in Chemistry at Middlebury College from 2013 to 2017. Nathaniel furthered their education by obtaining a Doctor of Philosophy degree in Chemistry from the University of California, Berkeley between 2019 and 2022.